Supernus Pharmaceuticals (SUPN) Q3 2026 earnings review
Supernus raises its standalone plan, but direct drug sales crawl
Supernus Pharmaceuticals, a maker of drugs for nervous system disorders, grew slower as last year's acquisition entered the comparison base. Total revenue rose 18% from a year ago, down from 32% growth last quarter, while direct product sales increased 6%. Operating profit excluding one-offs climbed 32% because last year's deal costs did not repeat, and chief executive Jack Khattar raised the standalone full-year outlook days before the Indivior merger closes on November 2.
| Net product sales | $178.6M +6% from a year ago |
|---|---|
| Total revenue | $226.8M +18% from a year ago |
| Operating profit, excluding one-offs | $55.2M +32% from a year ago |
| Full-year revenue outlook | Raised $12.5M retired when Indivior deal closes Nov 2 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because the quarter confirmed both the slowing top-line comparisons and the pending merger that will replace the standalone targets next week. On the positive side, ONAPGO Parkinson's pump sales rose 26% from last quarter, gained seven years of regulatory exclusivity, and got a filing for a second supplier. One caution: Qelbree ADHD sales grew 12% on 18% prescription growth, so net price per prescription fell 6% by our math.
The question now is whether the four newer drugs can outrun pharmacy rebate pressure and older drug declines once combined with Indivior. Optimists point to the 29% growth of those four medicines and $125 million in planned merger cost savings, while skeptics point to 6% direct product sales growth and slowing ZURZUVAE prescriptions. The combined company's first full-year outlook in early 2027 will settle the debate.
🐂 Bull Case
ONAPGO Gained Exclusivity and a Second Supplier
ONAPGO, an infusion pump for adults with advanced Parkinson's disease, brought in $17.1 million in third-quarter net sales. That figure rose 26.3% from the second quarter by our math, as prescriptions grew 17%. Demand stayed steady "with more than 400 enrollment forms submitted in the third quarter", matching the pace of the prior two quarters after supply limits ended in February.
Supernus also reduced two commercial risks around the drug. Regulators recognized "seven years of orphan-drug exclusive approval for ONAPGO for the treatment of motor fluctuations in adults with advanced Parkinson’s disease". In addition, the drugmaker filed an application with the Food and Drug Administration to add a second manufacturer, keeping a potential mid-2027 approval on schedule.
What to watch: ONAPGO fourth-quarter sales against the $23.5 million implied by the middle of the full-year outlook. Reaching that level would show the current single supplier can handle rising prescription volume before the backup factory arrives.
Profit Rebounded After Deal Costs Lapped
Operating profit excluding one-offs rose 31.7% from a year ago to $55.2 million, lifting the operating margin by 2.5 percentage points to 24.3% by our math. Under standard accounting, operating income swung to a $21.2 million profit from a $60.2 million loss a year earlier, because last year's third quarter carried $46.6 million of costs from buying Sage Therapeutics.
- Selling, general and administrative expense: 56.5% of revenue, down 37.1 percentage points from a year ago
- Research and development expense: 11.4% of revenue, down 3.9 percentage points from a year ago
- Cost of revenues (cost of making the drugs): 11.9% of revenue, up 2.0 percentage points from a year ago
What to watch: fourth-quarter operating profit excluding one-offs, which the full-year outlook puts at $54.8 million at the middle of the range by our math. Beating that figure would show the business is keeping its lower overhead costs as it enters the Indivior combination.
Four Newer Drugs Carry the Portfolio
Supernus relies on four newer medicines to replace its older epilepsy and Parkinson's drugs: Qelbree for attention-deficit hyperactivity disorder (ADHD), GOCOVRI and ONAPGO for Parkinson's disease, and ZURZUVAE for postpartum depression. Combined revenue from these four products grew 29% from a year ago to $192.2 million, making up 84.8% of total company revenue by our math.
Adults are driving the expansion in Qelbree, where adult prescriptions rose 25% from a year ago against 16% growth in children. GOCOVRI also reached an all-time high of $42.6 million in quarterly sales, up 4% on matching 4% prescription growth, while ZURZUVAE contributed $41.7 million in collaboration revenue from partner Biogen.
What to watch: adult prescription growth for Qelbree in the fourth quarter. Holding a pace near 25% would confirm that adult patients can keep lifting the brand even as pediatric growth stays in the mid-teens.
🐻 Bear Case
Headline Growth Masks Slow Product Sales
“Our strong operating execution year-to-date delivered total revenue growth of 29%, which shows the continued momentum across our commercial portfolio, specifically our growth products.” chief executive Jack Khattar said. That nine-month figure includes months when ZURZUVAE was not yet in the prior-year comparison, because Supernus closed the Sage acquisition on July 31, 2025.
Once ZURZUVAE entered the year-ago base for two months of the third quarter, total revenue growth slowed to 18.0% from 32.4% in the second quarter. Net product sales — drugs Supernus sells directly, excluding Biogen collaboration payments and royalties — grew 6.0% from a year ago to $178.6 million, and growth has decelerated across the main drivers.
- Qelbree net sales: up 12% to $90.8 million on 18% prescription growth, implying net price per prescription fell 5.9% from a year ago to $321 by our math
- ZURZUVAE US prescription growth: 43% from a year ago, down from 62% in the second quarter and 82% in the first quarter
- Fourth-quarter total revenue: 10.6% growth from a year ago implied by the middle of the full-year outlook by our math
What to watch: Qelbree net revenue per prescription in the fourth quarter, when insurance deductibles and pharmacy rebates typically reset. A reading below $320 by our math would show that rebates to pharmacy benefit managers are taking a larger cut of volume growth.
Legacy Drugs Shrink and Weigh on Accounting Profit
Older medicines that lost patent protection or face new rivals continue to shrink. Combined third-quarter sales of Oxtellar XR for epilepsy, APOKYN for Parkinson's disease, Trokendi XR for migraine and epilepsy, and smaller products fell 28.9% from a year ago to $28.1 million by our math, offsetting much of Qelbree's dollar gain.
Those past acquisitions also leave heavy charges on the income statement. Over the first nine months of 2026, Supernus recorded $74.2 million in intangible asset amortization and $56.5 million in impairment charges, mostly from writing down APOKYN last quarter. That left a nine-month operating loss of $45.1 million under standard accounting, even as operating profit excluding one-offs reached $115.2 million.
What to watch: fourth-quarter APOKYN net sales after their 38% drop to $6.5 million this quarter. Further declines at that pace could force another write-down of remaining intangible assets when the combined company closes its full-year books.
Risks This Quarter Didn't Answer
Several standing legal, pipeline and balance-sheet risks received no new financial detail or clinical data in the third-quarter release, leaving them open as the company combines with Indivior.
- Merger debt and cash payout: the release did not update how much of Supernus's $359.5 million cash pile will fund the special dividend to Indivior shareholders when the deal closes on November 2.
- Mid-stage clinical trials: Phase 2b studies for SPN-817 in epilepsy and SPN-820 in depression remain ongoing, with no enrollment counts or readout dates added; SPN-443 for ADHD still awaits Phase 1 initiation by year-end.
- Patent and antitrust litigation: the release gave no update on the January 2027 APOKYN antitrust trial, inherited Sage shareholder lawsuits, or upcoming generic entry for XADAGO in 2027 and GOCOVRI in 2029.
- ZURZUVAE profit share: Biogen collaboration costs were not broken out in the release, so the quarterly filing is needed to check the drug's net profit contribution.
👓 Other Themes
Indivior Merger Closes and Retires the Standalone Plan
Shareholders approved the all-stock merger with Indivior on October 15, and the deal closes on November 2, 2026. The combined business will trade as Supernus, Inc. and is "expected to realize $125 million in annual cost synergies". Management raised its standalone 2026 outlook but noted: "Assuming the merger is completed on November 2, 2026, we will operate as a combined company, and the guidance above will no longer apply."
💲 Other KPIs
Unrestricted cash and marketable securities dipped from $372.1 million at the end of June to $359.5 million, though the balance remains $50.8 million higher than at the end of 2025. Operating cash flow during the quarter was offset by paying off the $31.1 million ONAPGO launch milestone liability that sat on the June balance sheet.
Accounts receivable — money owed by drug wholesalers and partners for sales already booked — rose 25.4% from a year ago by our math, outpacing the 18.0% rise in total revenue. Since the end of 2025, receivables have grown by $26.9 million, tying up working capital as Qelbree and ONAPGO volumes expand.
Diluted shares rose 5.2% from a year ago by our math, up from 56.6 million in the prior-year period. Returning to a net profit under standard accounting added 1.3 million dilutive stock options and awards to the share count, and basic shares also rose by 1.6 million over the past year before the all-stock Indivior merger.
🔮 Guidance
Raised. The middle of the standalone plan moved up $12.5 million to $887.5 million, or 23.4% growth for the year by our math. That leaves $234.0 million for the fourth quarter, meaning growth slows to 10.6% from a year ago as the ZURZUVAE acquisition and last year's $15 million licensing milestone enter the comparison base. Second raise this year: $0M, +$20M, +$12.5M.
Unchanged at the middle of the range. Supernus raised the bottom of the target by $5 million and cut the top by $5 million, keeping the middle at $62.5 million. With $39.0 million booked in the first nine months, the plan requires $23.5 million in the fourth quarter by our math, a 37% jump from the third quarter.
Raised. The middle of the range rose by $8.5 million to $63.5 million because the two older drugs declined more slowly than planned in the first three quarters. With $52.3 million already booked through September, the outlook leaves $11.2 million for the fourth quarter by our math, down from $18.2 million in the third quarter.
Raised. The expected full-year operating loss under standard accounting narrowed by $12.5 million at the middle of the range to a loss of $22.5 million. Because the nine-month loss stands at $45.1 million after the second-quarter APOKYN write-down, the plan implies a $22.6 million operating profit in the fourth quarter by our math.
Raised. Supernus lifted the bottom of the range by $10 million, putting the middle at $170 million, or 7.1% growth for the year by our math. That leaves $54.8 million for the fourth quarter, a 23.4% margin on implied fourth-quarter revenue. It is the second raise this year: $0M, +$10M, +$5M.
❓ Key Questions
What is ZURZUVAE's net profit after Biogen's cost share?
Supernus booked $41.7 million in ZURZUVAE collaboration revenue, up from $35.4 million in the second quarter, when net contribution before amortization was only $7.2 million. The press release omits the shared expense lines needed to see if margins improved.
Why did Qelbree revenue per prescription drop 6%?
Qelbree prescriptions grew 18% from a year ago, but net sales rose only 12% to $90.8 million, cutting revenue per prescription to $321 by our math. Investors need to know if higher pharmacy rebates or pediatric mix drove the gap.
How many ONAPGO patients stay on the drug?
More than 400 patient enrollment forms arrived again this quarter, yet Supernus trimmed the top of its full-year ONAPGO sales target from $70 million to $65 million. Disclosing patient dropout rates would clarify the fourth-quarter ramp.
What will the combined balance sheet look like next week?
The Indivior merger closes on November 2 and retires standalone targets. Management has not yet detailed the opening cash balance, the exact debt load after the special dividend, or the timeline for the $125 million in annual cost savings.